Information Provided By: 
Fly News Breaks for July 19, 2017
PBYI
Jul 19, 2017 | 07:56 EDT
Post-FDA approval of Nerlynx, Leerink analyst Michael Schmidt raised his price target for Puma Biotechnology to $125 from $115 driven by a higher Nerlynx forecast now of $1.6B U.S. peak sales. The analyst reiterates an Outperform rating on the shares.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
